Neoadjuvant chemotherapy with bispecific antibody for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a bispecific antibody to chemotherapy before surgery helps treat advanced lung cancer better than a standard antibody. It is for people with stage II-III non-small cell lung cancer who have not had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer at stage II or III.
- You have not had any prior treatment for lung cancer, including surgery, radiation, or chemotherapy.
- You are generally healthy enough to undergo surgery.
- You do not have certain genetic mutations (EGFR or ALK) if your cancer is adenocarcinoma.
- You are willing to use effective birth control during the study and for 120 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This trial compares two treatments given before surgery for early-stage non-small cell lung cancer with high PD-L1. One group gets a new drug called cadonilimab, and the other gets a standard chemo plus an immunotherapy drug. The goal is to see which approach works better at shrinking tumors before surgery.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.